Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of docetaxel plus imatinib mesylate in metastatic breast cancer

Trial Profile

Phase II trial of docetaxel plus imatinib mesylate in metastatic breast cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 29 May 2016

At a glance

  • Drugs Docetaxel (Primary) ; Imatinib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Dec 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 02 Apr 2008 The expected completion date for this trial is now May 2009 according to ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top